Valeant
Losses and profit forecast cuts send shares tumbling again at Valeant
June 8, 2016Research and Development, Sales and Marketing Shares, Valeant, cut, forecast, tumbling
Valeant Pharmaceuticals has published its results for the first quarter, which has seen the firm post a net loss of …
Valeant announces expanded discounts for Nitropress and Isuprel
May 17, 2016Manufacturing and Production, Sales and Marketing Isuprel, Nitropress, Valeant, discounts
Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) …
Valeant announces new patient access and pricing committee; vows to correct past “mistakes”
May 6, 2016Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing
Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …
Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app
May 5, 2016Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons
IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …
Big investor hits back at critics as Valeant’s war of words gathers pace
May 3, 2016Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal
Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …
Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises
April 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises
Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …
Valeant names Joseph Papa as new chief executive officer
April 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson
Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …
Valeant receives further default notices due to its delayed 10-K filing
April 25, 2016Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry
Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …
Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Valeant bondholders issue notice to default
April 13, 2016Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility
Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …
Valeant’s ad hoc committee closes chapter on Philidor controversy
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee
Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016
April 4, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil
As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Valeant’s outgoing CEO subpoenaed by US congressional committee
March 29, 2016Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed
The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
Mylan launches generic of Valeant’s Ultram in the US
March 29, 2016Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …
Valeant CEO Pearson to leave company
March 21, 2016Michael Pearson, Valeant
Valeant (NYSE:VRX) has announced that it has begun the search for a new CEO, confirming that Michael Pearson is to …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
